2篇
您的检索式：作者名="Jialin She"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The heterogeneity of islet autoantibodies and the progression of islet failure in type 1 diabetic patients显示文摘Type 1 diabetes mellitus is heterogeneous in many facets. The patients suffered from type 1 diabetes present several levels of islet function as well as variable number and type of islet-specific autoantibodies. This study was to investigate prevalence and heterogeneity of the islet autoantibodies and clinical phenotypes of type 1 diabetes mellitus; and also discussed the process of islet failure and its risk factors in Chinese type 1 diabetic patients. A total of 1,291 type 1 diabetic patients were enrolled in this study. Demographic information was collected. Laboratory tests including mixed-meal tolerance test, human leukocyte antigen alleles, hemoglobin A1 c, lipids, thyroid function and islet autoantibodies were conducted. The frequency of islet-specific autoantibody in newly diagnosed T1 DM patients(duration shorter than half year) was 73% in East China. According to binary logistic regressions, autoantibody positivity, longer duration and lower Body Mass Index were the risk factors of islet failure. As the disease developed, autoantibodies against glutamic acid decarboxylase declined as well as the other two autoantibodies against zinc transporter 8 and islet antigen 2. The decrease of autoantibodies was positively correlated with aggressive beta cell destruction. Autoantibodies can facilitate the identification of classic T1 DM from other subtypes and predict the progression of islet failure. As there were obvious heterogeneity in autoantibodies and clinical manifestation in different phenotypes of the disease, we should take more factors into consideration when identifying type 1 diabetes mellitus. | Jin Liu Lingling Bian Li Ji Yang Chen Heng Chen Yong Gu Bingqin Ma Wei Gu Xinyu Xu Yun Shi Jian Wang Dalong Zhu Zilin Sun Jianhua Ma Hui Jin Xing Shi Heng Miao Bing Xin Yan Zhu Zhenwen Zhang Ruifang Bu Lan Xu Guangde Shi Wei Tang Wei Li Dongmei Zhou Jun Liang Xingbo Cheng Bimin Shi Jixiang Dong Ji Hu Chen Fang Shao Zhong Weinan Yu Weiping Lu Chenguang Wu Li Qian Jiancheng Yu Jialin Gao Xiaoqiang Fei Qingqing Zhang Xueqin Wang Shiwei Cui Jinluo Cheng Ning Xu Guofeng Wang Guoqing Han Chunrong Xu Yun Xie Minmin An Wei Zhang Zhixiao Wang Yun Cai Qi Fu Yu Fu Shuai Zheng Fan Yang Qingfang Hu Hao Dai Yu Jin Zheng Zhang Kuanfeng Xu Yifan Li Jie Shen Hongwen Zhou Wei He Xuqin Zheng Xiao Han Liping Yu Jinxiong She Mei Zhang Tao Yang | 2016 | Science China(Life Sciences)2016，59，9： | 5 |
| 2 | Near-Infrared Light-Responsive Nitric Oxide Delivery Platform for Enhanced Radioimmunotherapy显示文摘Radiotherapy(RT)is a widely used way for cancer treatment.However,the efficiency of RT may come with various challenges such as low specificity,limitation by resistance,high dose and so on.Nitric oxide(NO)is known a very effective radiosensitizer of hypoxic tumor.However,NO cannot circulate in body with high concentration.Herein,an NIR light-responsive NO delivery system is developed for controlled and precisely release of NO to hypoxic tumors during radiotherapy.Tert-Butyl nitrite,which is an efficient NO source,is coupled to Ag2S quantum dots(QDs).NO could be generated and released from the Ag2S QDs effectively under the NIR irradiation due to the thermal effect.In addition,Ag is also a type of heavy metal that can benefit the RT therapy.We demonstrate that Ag2S NO delivery platforms remarkably maximize radiotherapy effects to inhibit tumor growth in CT26 tumor model.Furthermore,immunosuppressive tumor microenvironment is improved by our NO delivery system,significantly enhancing the anti-PD-L1 immune checkpoint blockade therapy.100% survival rate is achieved by the radio-immune combined therapy strategy based on the Ag2S NO delivery platforms.Our results suggest the promise of Ag2S NO delivery platforms for multifunctional cancer radioimmunotherapy. | Xuanfang Zhou Zhouqi Meng Jialin She Yaojia Zhang Xuan Yi Hailin Zhou Jing Zhong Ziliang Dong Xiao Han Muchao Chen Qin Fan Kai Yang Chao Wang | 2020 | Nano-Micro Letters2020，12，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员